Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Erber R, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Liedtke C, Moustafa Z, Gluz O, Brünner N, Kreipe H, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 2015; 150:279-88.
Feb 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Feb 28, 2015
Breast Cancer Res Treat 2015; 150:279-88
Erber Ramona, Möbus Volker, Augustin Doris, Thomssen Christoph, Jänicke Fritz, Kiechle Marion, Kuhn Walther, Nitz Ulrike, Harbeck Nadia, Liedtke Cornelia, Moustafa Zehra, Gluz Oleg, Brünner Nils, Kreipe Hans Heinrich, Pelz Enrico, Kates Ronald, Bartels Annette, Huober Jens, Mohrmann Svjetlana, Hartmann Arndt
more
